Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Kura Oncology Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Kura Oncology Acquires Patent Rights of ERK Program from Araxes Pharma 11
Venture Financing 12
Kura Oncology Raises USD91.69 Million in Venture Financing 12
Partnerships 13
Kura Oncology Enters into Research Agreement with University of Michigan 13
Merger 14
Kura Oncology and Zeta Acquisition Complete Reverse Merger Transaction 14
Licensing Agreements 15
Kura Oncology Amends Licensing Agreement with Janssen Pharma 15
Kura Oncology Amends its Licensing Agreement with University of Michigan 17
Equity Offering 18
Kura Oncology Raises USD77.1 Million in Public Offering of Shares 18
Kura Oncology Raises USD53.5 Million in Public Offering of Shares 19
Kura Oncology Raises USD50 Million in Public Offering of Shares 21
Kura Oncology Raises USD60 Million in Private Placement of Common Stock 23
Kura Oncology Inc – Key Competitors 25
Kura Oncology Inc – Key Employees 26
Kura Oncology Inc – Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Financial Announcements 28
Aug 06, 2018: Kura Oncology reports second quarter 2018 financial results and provides corporate update 28
May 08, 2018: Kura Oncology Announces First Quarter 2018 Financial Results 30
Mar 12, 2018: Kura Oncology Provides Regulatory Update on Tipifarnib and Reports Fourth Quarter and Full Year 2017 Financial Results 32
Aug 07, 2017: Kura Oncology Reports Second Quarter 2017 Financial Results 34
May 15, 2017: Kura Oncology Reports First Quarter 2017 Operational and Financial Results 35
Mar 14, 2017: Kura Oncology Reports Fourth Quarter and Full Year 2016 Operational and Financial Results 37
Corporate Communications 38
Jul 31, 2018: Kura Oncology Appoints Marc Grasso, M.D., as Chief Financial Officer and Chief Business Officer 38
Jan 03, 2017: Kura Oncology Appoints Steven Stein, M.D. to Board of Directors 39
Legal and Regulatory 40
Jun 26, 2017: Kura Oncology added to Russell 3000 index 40
Product News 41
10/28/2017: Kura Oncology Development Candidate KO-539 Shows Robust Preclinical Anti-Tumor Activity in NPM1- and DNMT3A-Mutant AML 41
01/04/2017: Kura Oncology Nominates KO-539 as Development Candidate for Menin-MLL Inhibitor Program 42
Clinical Trials 43
Oct 16, 2017: Kura Oncology Announces Late-Breaking Presentation on KO-539 in AML at Upcoming AACR-NCI-EORTC International Conference 43
Apr 07, 2017: Kura Oncology Doses First Patient in Phase 1 Trial of ERK Inhibitor KO-947 44
Apr 05, 2017: Kura Oncology Presents Preclinical Data Demonstrating Significant Anti-Tumor Activity of KO-947 45
Apr 05, 2017: Kura Oncology Presents Preclinical Data on KO-539 at the American Association for Cancer Research Annual Meeting 2017 46
Mar 29, 2017: Kura Oncology to Present Preclinical Data on KO-539 at AACR Annual Meeting 2017 47
Mar 29, 2017: Kura Oncology to Present Preclinical Data on KO-947 at AACR Annual Meeting 2017 48
Jan 04, 2017: Kura Oncology Receives FDA Clearance to Proceed with Clinical Trial for ERK Inhibitor KO-947 49
Appendix 50
Methodology 50
About GlobalData 50
Contact Us 50
Disclaimer 50
Kura Oncology Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Kura Oncology Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Kura Oncology Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Kura Oncology Acquires Patent Rights of ERK Program from Araxes Pharma 11
Kura Oncology Raises USD91.69 Million in Venture Financing 12
Kura Oncology Enters into Research Agreement with University of Michigan 13
Kura Oncology and Zeta Acquisition Complete Reverse Merger Transaction 14
Kura Oncology Amends Licensing Agreement with Janssen Pharma 15
Kura Oncology Amends its Licensing Agreement with University of Michigan 17
Kura Oncology Raises USD77.1 Million in Public Offering of Shares 18
Kura Oncology Raises USD53.5 Million in Public Offering of Shares 19
Kura Oncology Raises USD50 Million in Public Offering of Shares 21
Kura Oncology Raises USD60 Million in Private Placement of Common Stock 23
Kura Oncology Inc, Key Competitors 25
Kura Oncology Inc, Key Employees 26
Kura Oncology Inc, Other Locations 27
List of Figures
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Kura Oncology Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9